On June 29, 2022, Selecta Biosciences, Inc. completed enrollment in its DISSOLVE II phase 3 clinical trial of SEL-212 for the treatment of chronic refractory gout. The Company expects to announce top-line results from this trial in the first quarter of 2023. Pursuant to the License and Development Agreement entered into between the Company and Swedish Orphan Biovitrum AB (Publ) (Sobi"), Sobi is obligated to pay the Company a $10 million development milestone payment within 15 days of being notified of the achievement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.43 USD | +0.34% | +24.85% | +27.79% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.79% | 47Cr | |
+9.42% | 11TCr | |
+11.84% | 11TCr | |
-2.42% | 2.2TCr | |
-14.15% | 2.19TCr | |
-5.29% | 1.92TCr | |
-4.16% | 1.81TCr | |
-38.29% | 1.77TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.24TCr |
- Stock Market
- Equities
- RNAC Stock
- News Cartesian Therapeutics, Inc.
- Selecta Biosciences, Inc. Completes Enrollment in Its Dissolve II Phase 3 Clinical Trial of SEL-212 for the Treatment of Chronic Refractory Gout